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https://doi.org/10.1016/j.chembiol.2020.06.012SUMMARYK-RAS is known as the most frequently mutated oncogene. However, the development of conventional K-
RAS inhibitors has been extremely challenging, with a mutation-specific inhibitor reaching clinical trials
only recently. Targeted proteolysis has emerged as a new modality in drug discovery to tackle undruggable
targets. Our laboratory has developed a system for targeted proteolysis using peptidic high-affinity binders,
called ‘‘AdPROM.’’ Here, we used CRISPR/Cas9 technology to knock in a GFP tag on the native K-RAS gene
in A549 adenocarcinoma (A549GFPKRAS) cells and constructed AdPROMs containing high-affinity GFPor H/K-
RAS binders. Expression of GFP-targeting AdPROM in A549GFPKRAS led to robust proteasomal degradation
of endogenous GFP-K-RAS, while expression of anti-HRAS-targeting AdPROM in different cell lines resulted
in the degradation of both GFP-tagged and untagged K-RAS, and untagged H-RAS. Our findings imply that
endogenous RAS proteins can be targeted for proteolysis, supporting the idea of an alternative therapeutic
approach to these undruggable targets.INTRODUCTION
The three RAS oncogenes, H-RAS, K-RAS, and N-RAS, repre-
sent the most frequently mutated genes in cancer (Cox et al.,
2014; Hobbs et al., 2016). They encode four highly similar pro-
teins, namely H-RAS, N-RAS, K-RAS4A, and K-RAS4B, which
undergo C-terminal farnesylation (Reiss et al., 1990; Schaber
et al., 1990). Farnesylation, in combination with palmitoylation
in the hypervariable region (HVR) (N-RAS, H-RAS, and K-
RAS4A) or with a polybasic signal in the HVR (K-RAS4B), medi-
ates the plasmamembrane interaction (Ahearn et al., 2012). RAS
proteins are small GTPases, which cycle between the GTP-
bound (active) and GDP-bound (inactive) states, controlled by
guanosine nucleotide exchange factors and GTPase activating
proteins (GAPs) (Vigil et al., 2010). Activation of RAS proteins
by various extracellular growth factors initiates activation of
numerous downstream signaling networks, including BRAF/
mitogen-activated protein kinase (MAPK) and phosphatidylino-
sitol 3-kinase pathways (Khan et al., 2019a), which are critical
for cell proliferation and viability. Many pathogenic mutations in
RAS genes impair GAP-mediated GTP hydrolysis, thereby favor-
ing the persistence of the active RAS-GTP state, which triggers
constitutive activation of downstream signaling resulting in un-
checked proliferation of cancer cells (Hobbs et al., 2016; Marcus
and Mattos, 2015).
As the oncogenicity of RAS mutations has been known for
over three decades, intensive efforts have been made towardCell Chemical Biology 27, 1–13, A
This is an open access article under the CC BY-Ndrugging them. These efforts are yet to result in effective RAS-in-
hibitor therapies (Cox et al., 2014; Papke and Der, 2017). This
has promoted the perception that RAS proteins are undrug-
gable. Several factors make RAS proteins difficult targets to en-
gineer selective small-molecule inhibitors. First, the relatively
high concentrations of GTP and GDP in cells and picomolar af-
finity to binding RAS proteins makes it almost impossible to
develop GTP/GDP analogs as inhibitors (Cox et al., 2014; John
et al., 1990). Second, structural analysis of RAS proteins re-
vealed few sufficiently large and deep hydrophobic pockets on
the surface for small-molecule binding (O’Bryan, 2019; Pai
et al., 1989). Recently, a covalent inhibitor targeting a cysteine
in K-RAS G12C was developed to target this specific mutation
(Ostrem et al., 2013). However, these barriers and failure to
directly target RAS have prompted researchers to explore tar-
geting upstream regulators, or downstream effectors of RAS
proteins (Cox et al., 2014; Kang et al., 2009; Leung et al., 2018;
Papke and Der, 2017; Waldmann et al., 2004), as well as altering
levels of RAS protein, for example, by inducing targeted degra-
dation of RAS (Nabet et al., 2018).
Most targeted protein degradation approaches harness the
cellular proteolytic pathways that naturally maintain proteosta-
sis, with the ubiquitin proteasome system (UPS) being frequently
exploited (Ro¨th et al., 2019). Protein degradation by the UPS is
triggered by conjugation of ubiquitin chains onto the target pro-
tein, which is achieved through a sequential action of three en-
zymes: the ubiquitin-activating enzyme (E1), which activatesugust 20, 2020 ª 2020 The Author(s). Published by Elsevier Ltd. 1
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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manner; a ubiquitin-conjugating enzyme (E2), which conjugates
the activated ubiquitin to its active site cysteine; and a ubiquitin
ligase (E3), which facilitates the transfer of ubiquitin from E2 to
primarily lysine residues on substrate proteins (Pickart and Ed-
dins, 2004; Roos-Mattjus and Sistonen, 2004). Further ubiquity-
lation on one or more lysine residues within ubiquitin then trig-
gers polyubiquitylation, followed by degradation by the
proteasome (Akutsu et al., 2016; Komander and Rape, 2012;
Yau and Rape, 2016). Targeting RAS for proteolysis relies on
the engagement of the cellular proteolytic systems for its ubiqui-
tylation and degradation. In this context, it has been shown that
the heterobifunctional molecule dTAG-13, which recruits
FKBP12F36V-tagged proteins of interest (POIs) to the CRBN/
CUL4A E3 ubiquitin ligase for their degradation, can degrade
FKBP12F36V-KRASG12V overexpressed in cell lines (Nabet
et al., 2018). However, FKBP12F36V itself can be targeted for
ubiquitylation when using heterobifunctional small-molecule
binders (Winter et al., 2015). Therefore, it remains unclear,
whether using dTAG13 on FKBP12F36V-K-RAS results in the
ubiquitination of K-RAS or FKBP12F36V. Such information is not
only key to evaluate proteolysis as a druggable approach for tar-
geting RAS proteins but also to inform on the development of
effective heterobifunctional RAS degraders.
We have previously developed an effective proteolytic affinity-
directed protein missile (AdPROM) system for UPS-mediated
POI degradation (Fulcher et al., 2016, 2017). AdPROM consists
of a fusion of von Hippel-Lindau (VHL) protein, a substrate
recruiter of the CUL2-RING E3 ligase complex, and high-affinity
binders, such as nanobodies and monobodies, of POIs. Deliv-
ering AdPROM into multiple cell lines through retroviral trans-
ductions led to efficient degradation of endogenous target pro-
teins, including SHP2 and ASC (Fulcher et al., 2017).
Furthermore, to target POIs for which no high-affinity polypep-
tide binders exist, we utilized CRISPR/Cas9 genome editing to
rapidly introduce GFP tags on endogenous VPS34 and PAWS1
genes, and used the AdPROM system consisting of anti-GFP
nanobody fused to VHL to achieve near complete degradation
of the endogenous GFP-VPS34 and PAWS1-GFP proteins
(Fulcher et al., 2016). In this study, we explore the use of the Ad-
PROM system, and demonstrate its efficacy, for targeted degra-
dation of endogenously GFP-tagged K-RAS and untagged,
endogenous K-RAS from cells.
RESULTS
Generation of a GFP-KRAS Knockin Non-small Cell Lung
Cancer A549 Cell Line
The high degree of amino acid sequence similarity between the
four RAS proteins, i.e., K-RAS4A, K-RAS4B, H-RAS, and N-RAS
(Figure 1A), and the subsequent difficulty in generating selective
antibodies against individual isoforms pose substantial chal-
lenges in studying specific RAS proteins (Waters et al., 2017).
To explore targeted proteolysis of K-RAS using the AdPROM
system, we used CRISPR/Cas9 technology to generate an
A549 non-small cell lung carcinoma (NSCLC) cell line harboring
a homozygous knockin of green fluorescent protein (GFP) cDNA
at the N terminus of the native K-RAS gene (Figure S1). As K-
RAS4A and K-RAS4B are splice variants differing only in their2 Cell Chemical Biology 27, 1–13, August 20, 2020extreme C terminus (Figure 1A), this approach allowed us to
simultaneously tag both isoforms with GFP. The homozygous
GFP knockins on the native KRAS locus (A549GFPKRAS) were
verified by genomic sequencing (Figure S1). Moreover, by west-
ern blot analysis using both panRAS and K-RAS4B antibodies,
the appearance of higher-molecular-weight GFP-K-RAS species
with a concurrent disappearance of the native-molecular-weight
K-RAS species was evident in the A549GFPKRAS cell line
compared with wild-type (WT) A549 control cells (Figure 1B).
The use of a panRAS antibody resulted in the detection of two
distinct bands in A549 WT cells (Figure 1B). As the lower band
remained intact in A549GFPKRAS cells, it most likely corresponds
to H- and/or N-RAS (Figure 1B). However, in A549 cells we were
unable to detect any endogenous signals with most commer-
cially available H-RAS-, N-RAS-, or K-RAS4A-specific anti-
bodies (listed in the STAR Methods). As K-RAS is an integral
part of the MAP kinase signaling pathway, we wanted to analyze
the effect GFP fusion would have on the MAPK signaling path-
ways. Under cell culture conditions, both MEK1/2 and ERK
phosphorylations were strongly decreased in A549GFPKRAS cells
compared with A549WT cells, while levels of BRAF were slightly
decreased (Figure 1B). Interestingly, phosphorylation of EGF re-
ceptor at Tyr1068 and AKT phosphorylation at Ser473 was
higher in A549GFPKRAS cells than in WT cells (Figure 1B). By
qRT-PCR, we showed that levels of H- and N-RAS transcripts
were slightly reduced in A549GFPKRAS cells compared with WT
A549 cells, while transcript levels of K-RAS were reduced by
roughly 50% (Figure S2). We were able to efficiently immunopre-
cipitate GFP-K-RAS from A549GFPKRAS but not WT A549 cell ex-
tracts (Figure 1C).
A number of RAS antibodies have been evaluated for selective
recognition of the different RAS proteins by western blotting
(Waters et al., 2017), but none of these have been selective for
use in immunofluorescence studies. Consequently, studies eval-
uating subcellular distribution of RAS proteins have been
restricted to overexpression systems. Validation of A549GFPKRAS
cells allowed us to investigate the subcellular distribution of
endogenous GFP-K-RAS driven by the native promoter. Endog-
enous GFP-K-RAS displayed predominantly plasma membrane
distribution, which was confirmed by co-staining with P120 cat-
enin, which is known to localize to the plasma membrane (Rey-
nolds et al., 1994) (Figures 1D and S3). In addition, we also
observed some weak cytoplasmic localization of GFP-K-RAS.
However, no co-localization of GFP-K-RAS was observed with
mitochondrial marker ATPB (Schatz and Butow, 1983) (Figures
1D and S3).
Finally, we compared turnover of WT K-RAS and GFP-K-RAS
proteins by adding cycloheximide to the respective cell line and
analyzing protein levels over the course of 12 h. We could not
find any remarkable differences in protein stability between WT
and GFP-K-RAS (Figures 1E and S4). However, as expected, a
robust degradation of c-myc was observed within 2–4 h
(Figure S4).
Targeted Degradation of GFP-K-RAS by the Proteolytic
AdPROM System
We sought to test whether endogenously expressed GFP-K-RAS
protein in A549GFPKRAS cells could be targeted for degradation by
AdPROM (Fulcher et al., 2016, 2017). We have previously shown
Figure 1. Generation of GFP-K-RAS Knockin
in A549 NSCLC Cells by CRISPR/Cas9
(A) Sequence Alignment of RAS protein isoforms
K-RAS4A (UniProt: P01116-1), K-RAS4B (Uniprot:
P01116-2), H-RAS (Uniprot: P01112-1), and N-RAS
(Uniprot: P01111-1). Degrees of shading according
to percentage sequence identity between the four
proteins. Asterisk denotes frequently mutated G12
position.
(B) A549 WT or K-RASGFP/GFP knockin (KI; hereafter
called A549GFPKRAS) cell lysates were separated by
SDS-PAGE and the indicated antibodies were used
for detection by western blotting. Arrows indicate
different RAS species (black, unmodified K-RAS;
dark gray, GFP-K-RAS; light gray, H-/N-RAS).
(C) Lysates were processed as in (B) and subjected
to immunoprecipitation with GFP-trap beads. I,
input; Ft, flowthrough; E, elution.
(D) Wide-field immunofluorescence microscopy of
untreated A549GFPKRAS cells labeledwith antibodies
specific for GFP (all left panels, cyan) and P120 (top
two middle panels, magenta) or ATPB (bottom two
middle panels, magenta), and DAPI (all left and
middle panels, blue). Overlay of GFP and P120/
ATPB is shown on the right. Scale bars, 10 mm. Two
representative images for each staining are shown.
(E) A549 WT (B) or A549GFPKRAS (D) cells were
treated with cycloheximide (100 mg/mL) and har-
vested at the indicated time points. Cell lysates
were further processed as in (B). Intensities of bands
corresponding to K-RAS or GFP-K-RAS were
quantified and normalized to GAPDH. Individual
values of three experiments are plotted together
with the curve of the average of those experiments,
relative to the corresponding t0 value. All blots are
representative of at least three independent exper-
iments.
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proteins, such as VPS34 and PAWS1, to the CUL2-RBX1 E3
ligasemachinery for target ubiquitination and subsequent protea-
somal degradation (Fulcher et al., 2016). Therefore, we postulated
that GFP-K-RAS could be recruited in a similar manner to the
CUL2-RBX complex for ubiquitination and degradation (Fig-
ure 2A). Indeed, expression of VHL-aGFP16 AdPROM resulted
in near complete clearance of GFP-K-RAS from A549GFPKRAS
cells comparedwith the untransducedcontrols, while the low-mo-
lecular-weight band corresponding toH- and/or N-RASwas unaf-
fected (Figure 2B). In contrast, neither VHL nor the aGFP16 nano-
body alone, serving as controls, caused any apparent changes in
the steady-state levels of GFP-K-RAS or other RAS proteins (Fig-
ure 2B). Treatment of VHL-aGFP16 AdPROM expressing
A549GFPKRAS cells with the Cullin neddylation inhibitor MLN4924
partially rescued the degradation of GFP-K-RAS compared with
DMSO-treated controls (Figure 2C). The neddylation of CUL2 al-
lowsa conformational changeof theCUL2-RBXE3 ligasemachin-
ery so that the RBX E3 ligase can ubiquitinate substrates recruitedCell Chby VHL. In line with this notion, the levels of
HIF1a protein, a bona fide substrate of VHL
(Yu et al., 2001), were stabilized upon
MLN4924 treatment compared with
DMSO control (Figure 2C). Despite the
high apparent efficiency of GFP-KRASdegradation by VHL-aGFP16 AdPROM, retroviral transduction
of A549GFPKRAS cells often generates uneven levels of AdPROM
expression in a mixed population of cells. To get a better under-
standing of the distribution of the cells within this population, we
used a flow cytometric analysis based on GFP fluorescence.
We used gates to define a GFP-positive population based on
the GFP signal from untransduced A549GFPKRAS cells and using
WT A549 cells as a GFP-negative control (Figure 2D). In accor-
dance with the western blot results (Figures 2B), 98% of cells
transduced with VHL-aGFP16 AdPROM virus showed GFP-
KRAS degradation as compared with untransduced A549GFPKRAS
cells (Figure 2D), which manifested in an overall reduction of GFP
fluorescence of the single-cell population (Figure 2E). The remain-
ing 2% of A549GFPKRAS cells produced GFP signal comparable
with untransduced GFP-positive-population, which could be
due to low-level AdPROM expression within these cells (Fig-
ure 2D). In contrast, A549GFPKRAS cells expressing VHL or
aGFP16 alone were defined as GFP positive at 99.3% or
99.8%, respectively (Figures 2D and 2E).emical Biology 27, 1–13, August 20, 2020 3
Figure 2. AdPROM-Mediated Degradation of GFP-K-RAS
(A) Schematic representation of the proteolytic AdPROM system. The high-affinity GFP-binder aGFP16 is fused to VHL, which is recruited by EloB and EloC to
Cul2. aGFP16 recruits GFP-tagged K-RAS and presents it in close proximity to RBX1 in the assembled Cul2 complex. Ubiquitin (Ub) is transferred onto K-RAS,
which is subsequently degraded (dashed lines and faded).
(B) After treatment with retroviruses and selection, cell lysates of indicated cell lines were separated on SDS-PAGE and analyzed by western blotting using the
indicated antibodies.
(C) Indicated cell lines were treated with 1 mM MLN4924 in 0.1% DMSO, or just DMSO at 0.1% for 24 h. Samples were further processed as in (B).
(D) Indicated cell lines were analyzed on a Canto flow cytometer. Shown populations were preselected for cells and single cells before defining the gate for GFP-
positive cells (shown). GFP-A is plotted against PE-A in all cases. Numbers indicate percentage of cells within the respective gate.
(E) Histogram representation of plots in (D). KI = A549 KRASGFP/GFP cells (referred to as A549GFPKRAS cells throughout text). Western blots are representative of at
least three independent experiments. Flow cytometry data are representative of two independent experiments.
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The AdPROM-mediated degradation of GFP-K-RAS in
A549GFPKRAS cells demonstrated the feasibility of targeted
degradation of endogenous K-RAS. However, the presence of4 Cell Chemical Biology 27, 1–13, August 20, 2020the GFP tag raises the possibility of ubiquitination occurring on
the GFP moiety, instead of K-RAS. Therefore, we sought to
explore whether we could exploit the AdPROM system to
degrade endogenous, unmodified K-RAS from A549 cells. At
present, there are no reported high-affinity, selective
Figure 3. Degradation of Endogenous RAS Using a RAS-Specific Monobody
(A) Cell lysates of indicated cell lines were subjected to immunoprecipitationwith anti-Flag beads. Input (I), flowthrough (Ft), and precipitates (IP) were run on SDS-
PAGE and subjected to western blotting with the respective antibodies.
(B) After retroviral transduction and selection, cell lysates of indicated cell lines were separated on SDS-PAGE and analyzed by western blotting using the
indicated antibodies.
(C) Indicated cell lines were treated with 1 mM MLN4924 or 0.1% DMSO for 24 h. Cell lysates were separated on SDS-PAGE and analyzed by western blotting
using the indicated antibodies.
(D) Indicated cell lines were analyzed on a Canto flow cytometer. Shown populations were preselected for cells and single cells before defining the gate for GFP-
positive cells (shown). GFP-A is plotted against PE-A in all cases. Numbers indicate percentage of cells within the respective gate.
(E) Histogram representation of plots in (D); KI = A549GFPKRAS cells.
(F)Wide-field immunofluorescencemicroscopy of indicated cell lines treatedwith anti-GFP antibody andDAPI for staining. Scale bars, 10 mm. Two representative
images are shown for each condition. Western blots and immunofluorescence data are representative of at least three independent experiments. Flow cytometry
data are representative of two independent experiments.
ll
OPEN ACCESSArticle
Please cite this article in press as: Ro¨th et al., Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System, Cell
Chemical Biology (2020), https://doi.org/10.1016/j.chembiol.2020.06.012polypeptide binders of K-RAS. However, we utilized an anti-H-
RAS (aHRAS) monobody that was reported to bind and immuno-
precipitate both H-RAS and K-RAS, but not N-RAS (Spencer-
Smith et al., 2017). Using this monobody with a FLAG tag, we
showed that anti-FLAG immunoprecipitates (IPs) could robustly
co-precipitate both GFP-tagged and untagged K-RAS as well as
the lower-molecular-weight protein band matching both H- and
N-RAS, which is most likely to be H-RAS (Spencer-Smith et al.,
2017) (Figure 3A). However, neither of the RAS proteins was
completely depleted from flowthrough extracts, suggesting
incomplete immunoprecipitation (Figure 3A). In contrast, anti-
FLAG IPs from extracts expressing Flag-VHL control did not
co-precipitate either protein (Figure 3A).Next, we sought to investigate whether AdPROM consisting of
VHL fused to aHRAS monobody could target K- and H-RAS pro-
teins for degradation. In A549GFPKRAS cells the expression of VHL-
aHRAS resulted in a strong reduction of the GFP-K-RAS protein
levels when compared with non-transduced, VHL or monobody
alone controls (Figure 3B). The degradation induced by VHL-aH-
RAS AdPROM was slightly less efficient than that achieved with
the VHL-aGFP16 AdPROM (Figure 3B). However, unlike VHL-
aGFP16, VHL-aHRASalso reduced the protein levels correspond-
ing to the H-RAS and/or N-RAS band (Figure 3B). The loss in pro-
tein levels of endogenous H-RAS protein caused by VHL-aHRAS
AdPROM could be rescued by the Cullin neddylation inhibitor
MLN4924, suggesting that the degradationwasmediated throughCell Chemical Biology 27, 1–13, August 20, 2020 5
Figure 4. Degradation of Endogenous Unmodified RAS Using a RAS-Specific Monobody
(A) SDS-PAGE and western blot analysis of A549 cells transduced with indicated plasmids with indicated antibodies.
(B) Post-puromycin selection, transduced cells, or non-selected A549WT cells, were treatedwith 40 mMMG132, 10 mMbortezomib, or DMSO (all at 0.2%DMSO)
for 14 h before harvest.
(C) RNA from A549 cells transduced with and selected for the indicated plasmids was reverse transcribed and screened for mRNA levels by qRT-PCR for the
indicated genes, normalized to GAPDH. Error bars (SD) are shown for n = 3 (except K-RAS4A VHL-aGFP16 and VHL, n = 2). Unpaired ordinary one-way ANOVA
with Dunnett’s multiple comparisons test has been performed.
(D) Volcano plots of proteins identified in tandem mass tag total proteome analysis in A549 cells transduced with and selected for VHL-aHRAS compared with
empty vector control (EV) (left) or VHL alone (right). Horizontal line shows significance level of p = 0.05. Vertical lines show 2-fold change. Positions of KRAS,
HRAS, NRAS, and VHL are indicated.
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We also assessed the relative abundance of GFP-K-RAS
in mixed populations of A549GFPKRAS cells transduced with
VHL-aHRAS AdPROM in comparison with controls by flow cy-
tometry. We found that 77% of cells showed degradation of
GFP-K-RAS, as assessed by the shift of the GFP-positive gated
population toward the GFP-negative population (Figure 3D) and
the overall reduction of GFP signal (Figure 3E). The remaining
23% of cells transduced with VHL-aHRAS were seemingly unaf-
fected in terms of GFP level (Figures 3D and 3E). Transductions
with VHL or aHRAS alone did not induce any noticeable shift of
the GFP population or GFP signal intensity (Figures 3D and 3E).
Uneven retroviral transduction of cells could result in unequal
expression of the AdPROM constructs in different cells resulting
in a mixed, divergent cell population, which may account for the
apparent uneven degradation of GFP-K-RAS through VHL-aH-
RAS. When we analyzed these A549GFPKRAS mixed cell popula-
tions by immunofluorescence for GFP signal, in non-transduced
and aHRAS-transduced control cells, a predominant plasma
membrane GFP-K-RAS signal was evident (Figure 3F). Trans-
duction of A549GFPKRAS cells with either VHL-aHRAS or VHL-
aGFP16 AdPROM produced a heterogeneous population6 Cell Chemical Biology 27, 1–13, August 20, 2020comprising cells with missing or severely attenuated GFP signal,
and cells with intact GFP-K-RAS staining pattern, localizing
mainly to the plasma membrane (Figure 3F). In contrast, we
noticed a slight increase in endoplasmic reticulum (ER)/perinu-
clear GFP-K-RAS signal in cells transduced with the aHRAS
monobody alone (Figure 3F). Interestingly, we detected that
themajority of themonobody itself was in the nucleus (Figure S5),
while we were unable to consistently detect signals for the Ad-
PROM fusion proteins by anti-FLAG immunofluorescence
(Figure S5).
AdPROM-Mediated Degradation of Untagged
Endogenous RAS Proteins
Having verified that VHL-aHRAS AdPROM recognizes and de-
grades GFP-K-RAS, we next tested its ability to degrade endog-
enous K- and H-/N-RAS in WT A549 cells. The transduction of
cells with VHL-aHRAS resulted in a substantial reduction in
apparent levels of both K-RAS (upper band) and H-/N-RAS
(lower band) proteins as detected by the panRAS antibody and
compared with the non-transduced controls (Figure 4A). Unlike
in A549GFPKRAS cells (Figure 3B), WT cells transduced
with VHL-aGFP16 AdPROM did not display any noticeable
changes in K-RAS and H-/N-RAS protein levels relative to
Table 1. Proteins Identified in Total Proteome Analysis in Comparison of VHL-aHRAS versus VHL Transduced Cells, as Either 2-Fold
More or Less Abundant
Classification Protein Uniprot ID
VHL-
aHRAS/VHL VHL-aHRAS/EV VHL/EV
Fc p Value Fc p Value Fc p Value
VHL-aHRAS >2-fold decrease Neuronal pentraxin-1 (NPTX1) Q15818 0.348 0.00607 0.961 0.77092 3.028 0.01113
H-RAS P01112 0.464 0.01404 0.466 0.01391 0.998 0.84955
VHL-aHRAS >2-fold increase TFIID subunit 4B (TAF4B) Q92750 4.875 0.012 3.598 0.03235 0.801 0.25714
LBH Q53QV2 2.847 0.00527 1.942 0.08367 0.682 0.38491
Annexin A8-like protein 1 (ANXA8L1) Q5VT79 2.434 0.03474 1.487 0.20081 0.511 0.68722
Enhancer of filamentation 1 (NEDD9) Q14511 2.268 0.00515 1.508 0.01131 0.72 0.04447
Transgelin (TAGLN) Q01995 2.176 0.00251 1.823 0.00281 0.838 0.26401
M-RAS O14807 2.079 0.00114 2.017 0.05143 1.013 0.48323
K/N-RAS K-RAS P01116 0.909 0.48915 0.841 0.01985 0.886 0.59775
N-RAS P01111 0.984 0.84292 1.082 0.82715 1.036 0.86126
VHL and targets VHL P40337 1.952 0.00117 9.313 0.00018 4.686 0.00104
MYBBP1A Q9BQG0 0.988 0.73087 0.886 0.47828 0.857 0.60345
RPB1 P24928 1.028 0.78989 0.991 0.75666 0.987 0.24496
Values of identified proteins are given for VHL-aHRAS versus empty vector (EV) and VHL versus EV-transduced cells as well. UniProt ID is given, as well
as fold change (Fc) values and p values for the respective comparison. In addition, results are shown for K- and N-RAS, as well as VHL and two
described VHL substrates.
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nature of RAS degradation by AdPROM. Cells transduced with
the aHRAS monobody alone showed a slight increase in abun-
dance of both K-RAS and H-/N-RAS proteins compared with
non-transduced controls (Figure 4A). To ascertain whether Ad-
PROM-mediated degradation occurs via the proteasome, we
treated A549 cells expressing the VHL-aHRAS AdPROM system
or A549 WT cells with proteasomal inhibitors MG132 and borte-
zomib, both of which resulted in a strong accumulation of poly-
ubiquitinated proteins (Figure 4B). In A549 WT cells, RAS protein
levels increased only slightly after 14 h ofMG132 and bortezomib
treatment. In contrast, in VHL-aHRAS AdPROM cells, both bor-
tezomib and MG132 rescued RAS protein levels, with bortezo-
mib rescuing it to levels comparable with A549 WT cells (Fig-
ure 4B). Next, we sought to explore whether RAS protein
degradation triggers a change in RAS transcript levels. We trans-
duced A549 WT cells with constructs encoding Flag-VHL-aH-
RAS, Flag-aHRAS, Flag-VHL-aGFP16, or Flag-VHL and a
pBabeD empty construct as a calibrator. While we noticed a
slight increase in K-RAS4A transcripts in cells expressing aH-
RAS or VHL-aHRAS relative to other cells, these changes were
not statistically significant (Figure 4C).
Next, we looked at the global quantitative proteomic changes
upon targeted degradation of RAS proteins through the Ad-
PROM system. To this end, we used puromycin-selected cells
transduced with pBabeD empty vector, a plasmid encoding
Flag-VHL-aHRAS, or a plasmid encoding for Flag-VHL, and per-
formed tandem mass tag-labelled total proteome analysis (Fig-
ures 4D and S6). We found that H-RASwas significantly reduced
by more than 50% in VHL-aHRAS samples, compared with both
VHL alone and the empty vector controls (Figure 4D, Table 1). K-
RASwas significantly reduced by15% in VHL-aHRAS samples
compared with empty vector; however, the reduction was not
significant when compared with VHL alone control. N-RAS wasunchanged in all conditions, further consolidating the specificity
of the monobody toward the H- and K-RAS isoforms (Spencer-
Smith et al., 2017). Interestingly, in VHL-aHRAS samples the
only proteins significantly downregulated by a factor higher
than 2 when compared with VHL alone were H-RAS and
NPTX1, the latter, however, most likely stemmed from upregula-
tion by VHL, as the increase was observed in the ‘‘VHL alone’’
sample and it was not changed when compared with the empty
vector (Table 1). To our surprise, M-RAS protein abundance
increased by 2-fold in cells expressing VHL-aHRAS. In addition,
transcription initiation factor TFIID subunit 4B (TAF4B) was more
than 3-fold more abundant in the VHL-aHRAS-expressing cells
compared with controls (Table 1). The abundance of transcrip-
tion factor LBH, Annexin-A8-like protein 1 (ANXA8L1), NEDD9,
and Transgelin also increased >1.5-fold in VHL-aHRAS-express-
ing cells compared with controls (Table 1). VHL abundance was
roughly 9-fold higher in the VHL-aHRAS-transduced samples
compared with the empty vector control and 2-fold higher
compared with VHL alone samples (Table 1). While we could
not detect HIF1a, we found that overexpression of VHL, either
alone or when fused to the aHRAS monobody, did not signifi-
cantly change protein levels of other VHL substrates (Zhang
and Yang, 2012) MYBBP1A (Lai et al., 2011) or RNA polymerase
II subunit RPB1 (Kuznetsova et al., 2003).
Expansion of the RAS-Targeting AdPROM System in
Different Cell Lines
Having demonstrated for the first time that the VHL-aHRAS Ad-
PROM system could target endogenous, unmodified H- and K-
RAS for degradation in A549 cells, we sought to explore whether
the system would work in other cell lines. First, we compared
different cell lines for their endogenous RAS protein expression
(Figure 5A) relative to A549 cells. All cells tested displayed K-
RAS protein expression similar to, or slightly lower than, A549Cell Chemical Biology 27, 1–13, August 20, 2020 7
Figure 5. Degradation of RAS in Different Cell Lines and Effects on Proliferation
(A–C) Lysates of untreated (A) or retrovirally transduced cell lines (indicated expression constructs) (B) were separated by SDS-PAGE and analyzed by western
blotting with the indicated antibodies. Comparison of cell lines in (A) was done only once. K-RAS mutation statuses for individual cell lines are indicated in
brackets. (C) A total of 5,000 cells from (B) or A549 cells from (Figure 4A) or (Figure 3B) were grown in triplicate in 12-well dishes. After 7 days, cells were fixed and
stained with crystal violet. A representative image of the replicates is shown.
(D) Staining fromplates in (C) was extracted bymethanol and absorbance at 570 nmwasmeasured. Plotted 570-nm values are relative to the respective untreated
sample. The number of biological replicates (applies to western blots in (B) as well) is indicated next to the cell line and error bars (SD) are shown. For statistical
analysis one-way ANOVA analysis with Dunnett’s multiple comparisons test was done. Comparisons were drawn to the untreated sample. *p < 0.05; **p < 0.01.
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(Morandi et al., 2012), displayed similar levels of expression to
A549 cells; however, we noticed that K-RAS in this cell line pro-
duced a slight but noticeable molecular weight shift when8 Cell Chemical Biology 27, 1–13, August 20, 2020probed with panRAS and K-RAS4B antibodies (Figure 5A). Pro-
tein levels corresponding to the lower H- and/or N-RAS band
were similar in all lines tested but overall, much lower in intensity
than that seen for K-RAS. We tested the ability of VHL-aHRAS
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In HT-29 cells, which express WT RAS proteins but harbor the
activating BRAF V600Emutation (Tan et al., 2008), only the levels
of H-RAS but not K-RAS proteins were reduced by VHL-aHRAS
AdPROM compared with controls (Figure 5B, left panel). For
SW620 cells, which harbor the G12V mutation of K-RAS, we
noticed a high K-RAS signal to H-/N-RAS signal ratio, as the
latter was barely detectable (Figure 5B, right panel). We
observed stabilization of K-RAS with the aHRAS monobody
alone, while VHL-aHRAS failed to degrade K-RAS compared
with controls.
Finally, we wanted to explore whether targeted degradation of
K- and H-RAS proteins from WT A549, HT29, and SW620 cells
using the VHL-aHRAS AdPROM, and GFP-K-RAS from
A549GFPKRAS cells using the VHL-aGFP16 AdPROM would
impact cell proliferation. No significant differences in prolifera-
tion could be observed for either WT A549 or A549GFPKRAS cells
following AdPROM-mediated degradation of the respective RAS
proteins compared with controls after 7 days, as measured by
crystal violet staining (Figures 5C and 5D). Although A549 cells
harbor the oncogenic KRASG12S mutation, they also harbor
over 250 genetic mutations (COSMIC cell lines project) (Tate
et al., 2018), including some known oncogenes and tumor sup-
pressors reducing the likelihood that these cells are solely
dependent on the K-RASG12S oncogene for their proliferation.
Interestingly, proliferation of HT-29 cells was reduced by about
50% by the aHRAS monobody alone (Figures 5C and 5D), while
the VHL-aHRAS and VHL-aGFP16 constructs reduced growth to
a lesser extent (Figure 5D). Both the aHRAS monobody alone
and the VHL-aHRAS AdPROM, but not VHL-aGFP16 AdPROM
were able to reduce the proliferation of SW620 cells significantly
by about 50% (Figures 5C and 5D).
DISCUSSION
Overexpression of GFP-tagged or other epitope-tagged K-RAS
has been used frequently to investigate RAS localization (Schmick
et al., 2014; Spencer-Smith et al., 2017; Tsai et al., 2015). This
overcomes the difficulty in the study of RAS proteins in the
absence of robust reagents to reliably detect specific RAS pro-
teins at the endogenous levels, especially by immunofluores-
cence (Waters et al., 2017). Our homozygous A549GFPKRAS
NSCLC cell line, generated using CRISPR/Cas9, has allowed us
not only to assess localization of endogenously driven GFP-K-
RAS protein, but its mobility shift has allowed us to test the utility
of panRAS and K-RAS antibodies in detecting K-RAS by western
blotting. However, our results also prompt cautious use of GFP-
tagged K-RAS, as A549GFPKRAS exhibit a drastically altered phos-
phorylation status for downstream targets MEK1/2, ERK1/2, and
AKT, as well as EGFR. This, of course, might be related to clonal
variation; however, in screening for GFP-positive cells following
CRISPR-mediated GFP-K-RAS knockin, we only obtained one
viable clone, perhaps hinting at a low tolerance for the presence
of GFP on endogenous K-RAS. Beyond the plasma membrane
localization, we observed additional disperse cytoplasmic signals
of endogenous GFP-K-RAS, but no mitochondrial localization.
When overexpressed, K-RASG12V has been suggested to be
transported intomitochondria, leading to alterations ofmembrane
potential, a decrease in respiration, and an increase in glycolysis(Hu et al., 2012). Potential compartments for the observed cyto-
solic signal for K-RAS could be Golgi, as seen for H- and N-RAS
(Goodwin et al., 2005), which could correspond to K-RAS4A
signal, or ER. However, this remains to be verified.
In this report, we demonstrate that endogenous K-RAS and
H-RAS proteins can be targeted for degradation using the pro-
teolytic AdPROM system. RAS proteins have remained elusive
targets for anti-cancer therapies, primarily due to their undrugg-
ability (Cox et al., 2014). Research into obtaining small-molecule
inhibitors of K-RAS has been carried out for over 30 years
without much success (Cox and Der, 2010). Recently, RAS-tar-
geting small molecules have emerged, with specificities to (1) a
specific mutation status of K-RAS (G12C), i.e., ARS-1620 (Janes
et al., 2018), and ARS-853 (Patricelli et al., 2016); (2) K-RAS, in-
dependent of the mutation status (McCarthy et al., 2019); or (3)
RAS proteins in either nucleotide bound state (Kessler et al.,
2019). Two compounds targeting K-RASG12C mutation,
AMG510 and MRTX849, are currently undergoing clinical trials
(Lindsay and Blackhall, 2019). An alternative approach has
been the development of high-affinity polypeptide binders of
RAS that neutralize the RAS function. A class of binders based
on ankyrin repeat proteins (Guillard et al., 2017) can bind and
neutralize specific nucleotide loading states of RAS proteins
(Guillard et al., 2017). Similarly, a fibronectin type III domain-
based RAS binding monobody (Khan et al., 2019b; Koide
et al., 1998; Spencer-Smith et al., 2017, 2019) was shown to
bind and inhibit the dimerization of both K- and H-RAS, and
the overexpression of this monobody was shown to suppress tu-
mor growth in mice (Khan et al., 2019b). Besides inhibition, RAS
degradation offers another alternative approach at inhibiting
RAS function to target RAS-dependent cancer cells. In this
context, the dTAG-13 proteolysis targeting chimera (PROTAC)
was used to degrade FKBP12F36V-tagged K-RAS (Nabet et al.,
2018) through the UPS, albeit when overexpressed in cells.
Our AdPROM system demonstrates that endogenous RAS pro-
teins can be targeted for proteolysis through the UPS and sug-
gests that pharmacological targeting of RAS proteins for protea-
somal degradation is a viable option for intervention. Although
targeted delivery of polypeptide binders of RAS proteins or the
proteolytic AdPROM system into RAS-dependent cancer cells
remains challenging and currently offers limited therapeutic po-
tential, these are excellent tools to provide the proof of concept.
Further optimization of efficient AdPROM gene or protein deliv-
ery technologies might enable the study of short-term responses
in downstream signaling of RAS. In the clinic and for a thorough
analysis of degradation kinetics, cell-permeable small-molecule
PROTACs are more viable options than the current AdPROM
system, as it relies on long antibiotic selection for transduced
cells and in its current form is not tractable. Recently two allo-
steric small-molecule binders were described for K-RAS with
micromolar and nanomolar binding affinities (Kessler et al.,
2019; McCarthy et al., 2019). It would be important to test these
binders’ capabilities as K-RAS targeting warheads in a PROTAC
approach, similar to the recently published ones (Bond et al.,
2020; Zeng et al., 2020). In this context, a re-evaluation of RAS
binding molecules, with or without inhibitory function, might
prove successful for PROTAC design. Work published while
this study was under review utilizing a KRASG12C-specific PRO-
TAC harboring a CRBN recruiting warhead was able toCell Chemical Biology 27, 1–13, August 20, 2020 9
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was unable to degrade endogenous or untagged K-RAS (Zeng
et al., 2020). Based on these results, this study suggested that
targeting endogenous K-RAS for degradation by the protea-
some would be difficult, if not impossible. However, our study
here demonstrates that VHL-aHRAS AdPROM clearly targets
both endogenous H- and K-RAS proteins for degradation
through the proteasome. Moreover, a very recent preprint study
has demonstrated that a VHL-recruiting K-RASG12C-specific
PROTAC is indeed able to degrade endogenous K-RASG12C in
different cell lines, although its impact on the viability of different
cell lines after PROTAC treatment over the K-RASG12C inhibitors
is yet to be addressed (Bond et al., 2020). It has been shown that
cells that undergo long-term PROTAC treatment can gain resis-
tance mutations in the E3 ligases or their receptors, which stop
the PROTAC-E3 interaction (Zhang et al., 2019). In the search
for other E3 ligases applicable for PROTAC development, the
AdPROM system represents a rapid research tool with the po-
tential to screen the efficacy of different E3 ligases, or RAS pep-
tide recruiters in degradation of RAS. In addition, our
A549GFPKRAS cells provide an excellent high-throughput
screening platform to test the efficacy of either new E3warheads
that are compatible with RAS degradation, or new RAS-recruit-
ing warheads.
The field of targeted RAS proteolysis is gaining momentum
and presents different approaches for different applications.
While the dTAG system offers strong, selective, andmore impor-
tantly inducible degradation of POIs, it relies on the fusion of
FKBP12F36V to the N terminus of RAS (Nabet et al., 2018), which
in an endogenous setting might pose problems similar to the ef-
fects GFP fusion imposed on K-RAS. In contrast, with the Ad-
PROM system, we were able to degrade endogenous, unmodi-
fied RAS proteins, albeit constitutively, which in turn might have
allowed cells to adapt to RAS degradation by the time we could
perform the analysis of changes in signaling and proliferation.
These limitations can be overcome by K-RAS-directed PRO-
TACs which can combine direct degradation of K-RAS with the
benefit of small-molecule delivery omitting overexpression of
components. However, currently there is a dearth of K-RAS-
directed PROTACs, with only two studies reporting the develop-
ment of K-RAS-G12C-directed PROTACs (Bond et al., 2020;
Zeng et al., 2020), while binders for other RAS mutation states
are still missing. Nonetheless, in addition to being invaluable
research tools, the AdPROM and dTAG systems offer excellent,
rapid screening platforms to inform development of PROTACs.
While the VHL-aGFP AdPROMwas very effective at selectively
degrading GFP-K-RAS from A549GFPKRAS cells, the VHL-aHRAS
AdPROM degraded endogenous H- and K-RAS with mixed effi-
cacy in different cell lines. In developing the aHRAS monobody,
the authors noted a difference in downstream behaviors of H-
and K-RAS upon monobody binding, such as K-RAS, but not H-
RAS being displaced from the membrane, or the mutant K-RAS,
but not mutant H-RAS interaction with RAF being disturbed by
monobody binding (Spencer-Smith et al., 2019). The full determi-
nants of interaction between the aHRAS monobody and different
H- and K-RAS mutants or any post-translationally modified forms
remain poorly defined. It is perhaps the differences in affinity be-
tween the RAS proteins and the aHRAS monobody that define
how robustly or poorly VHL-aHRAS can degrade different RAS10 Cell Chemical Biology 27, 1–13, August 20, 2020proteins, as the initially described binding preference of themono-
body to H-/K-RAS, but not N-RAS (Spencer-Smith et al., 2017), is
reflected in different levels of degradation when used in the Ad-
PROM system (Table 1). Nevertheless, VHL-aHRAS-mediated
RAS degradation was enough to elicit a cellular response to the
removal of RAS proteins from a cell. Our data indicate a respon-
sive upregulation of both M-RAS and TAF4B in A549 cells. Over-
expression of M-RAS with activating mutations has been shown
to lead to ERK signaling activation and transformation of cells
(Quilliam et al., 1999). TAF4B, on the other hand, is usually asso-
ciated with oocyte development (Falender et al., 2005a) and sper-
matogenesis (Falender et al., 2005b), and has not beenassociated
with RAS function before. However, these findings need to be
corroborated further.
In our system, it is unclear whether ubiquitination occurs on
RAS itself, and/or the monobody, although complex formation
would suggest that, within the AdPROM setup, VHL and the
monobody are further from the RBX1 ubiquitination zone than
bound RAS. In the same line of reasoning, N-terminal GFP of
GFP-K-RAS would be even closer to RBX1, which might explain
the strong degradation of GFP-K-RAS with VHL-aHRAS. None-
theless, our study strongly suggests that different high-affinity
polypeptide binders that can selectively bind either specific
RAS proteins or mutants can be packaged with VHL-AdPROM
to target specific RAS proteins for proteasomal degradation. At
the same time, endogenous VHL substrates are not affected
by the apparent overexpression of VHL (Table 1). We also noted
that aHRAS monobody alone resulted in a marked stabilization
of both H-RAS and K-RAS in multiple cell lines (Figures 4A and
5B). This effect could be caused either by a feedback loop
induced by the inhibition of both RAS species imparted by aH-
RAS binding, or by blocking the natural turnover pathway
through binding the RAS dimerization interface at helical struc-
tures a4-a5 (Spencer-Smith et al., 2017).
For the cell lines that we used, AdPROM-mediated degradation
of H-/K-RAS was not sufficient to induce inhibition of anchorage-
dependent cell proliferation. Despite harboring an activating K-
RASG12S mutation, A549 cells do not appear to be strictly depen-
dent on K-RAS alone in anchorage-dependent growth. While
A549 cells are often discussed to be K-RAS independent (Kazi
et al., 2018; Singh et al., 2009; Symonds et al., 2016), expression
of MiR-181a-5p, a microRNA targeting the K-RAS 30 UTR,
reduced A549 anchorage-dependent proliferation and migration.
However, MiR-181a-5p does not target K-RAS selectively (Ma
et al., 2015). Many RAS-dependent cell proliferation assays use
anchorage-independent 3D cultures. For example, the K-
RASG12C drug ARS-1620 was shown to be effective at inhibiting
RAS-dependent cell proliferation in 3D cultures but not in 2D cul-
tures (Janes et al., 2018). In a similar manner, EGFR inhibitors
show anti-proliferative effects in A549 cells only in an
anchorage-independent growth context (Jaramillo et al., 2008).
In contrast, SW620 cells, which are considered to be K-RAS
dependent (Kazi et al., 2018; Singh et al., 2012), were inhibited
in anchorage-dependent proliferation by aHRAS monobody
alone. VHL-aHRASAdPROM,which caused nodetectable degra-
dation of K-RAS in these cells, did not inhibit their proliferation any
further. The inhibition of cell proliferation of RAS-dependent cells
by aHRAS monobody is consistent with previous reports (Khan
et al., 2019b; Spencer-Smith et al., 2017). The lack of degradation
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size shift of K-RAS in these cells, possibly caused by a post-trans-
lational modification or a mutation that might allow binding to aH-
RAS monobody but prevent ubiquitination by the VHL-AdPROM,
although this needs to be defined further. However, considering
the length of the transduction and the antibiotic selection process
the current AdPROM system uses, at the time of proliferation
tests, only cells that have overcome the antiproliferative effects
of RAS degradation might be selected. Therefore, to assess the
effects of AdPROM-mediated degradation of H-/K-RAS on prolif-
eration robustly, it will be essential to first obtain high-affinity poly-
peptide RAS binders that bind to specific RAS proteins and then
use them in RAS-dependent cell lines using a tractable AdPROM
system by either delivering AdPROM proteins or a chemically
inducible AdPROM system.SIGNIFICANCE
Our findings demonstrate clearly that endogenous RAS pro-
teins can be targeted for proteasomal degradation by using
the AdPROMsystem. The systemunequivocally informs that
targeted proteolysis of endogenous K-RAS is a viable strat-
egy to target K-RAS-dependent pathologies. The findings
open up exciting opportunities to develop VHL-recruiting
K-RAS-specific cell-permeable PROTACs as potential ther-
apeutic agents. Our findings also highlight the need for
developing better and more selective RAS binding polypep-
tides, such as nanobodies or monobodies, to achieve more
selective degradation with the AdPROM system.STAR+METHODS
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Deposited Data
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TMT9plex-Related to Figure 4D
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Data obtained in this study This paper osf.io/zm3dx
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Sequences – Related to STAR Methods
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Services
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pX335 KRAS Nter KI AntiSense This paper; MRCPPU Reagents and
Services
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pMK-RQ KRAS G12S Nter GFP donor This paper; MRCPPU Reagents and
Services
Cat# DU57406
pBABED P FLAG aHRAS nanobody This paper; MRCPPU Reagents and
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Software and Algorithms
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SoftWoRx GE Healthcare N/A
OMERO Allan et al., 2012 http://openmicroscopy.org/
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Materials Availability
Plasmids generated in this study can be obtained from MRC PPU Reagents and Services (https://mrcppureagents.dundee.ac.uk/).
Data and Code Availability
Original data have been deposited to the Center for Open Science repository: osf.io/zm3dx
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines
A549GFPKRAS cells were derived from the epithelial lung cancer cell line A549 by CRISPR/Cas9 mediated knock-in of GFP CDS to the
KRAS locus. A549 cells were derived from a 58 year old Caucasianmale. A375 cells are amalignant melanoma cell line from a 54 year
old female. A172 cells are glioblastoma cells from a 53 year oldmale. SW620 cells are Duke’s type C colorectal adenocarcinoma cells
derived from the lymph node metastatic site of a 51 year old Caucasian male. HT-29 cells are colorectal adenocarcinoma cells
derived from a primary tumor from a 44 year old Caucasian female. HPAFII cells are pancreatic adenocarcinoma cells derived
from peritoneal ascitic fluid of a 44 year old Caucasian male. H460 cells are large cell lung cancer cells derived from pleural effusion
of a male patient. HEK293-FT cells are a clonal isolate of HEK293 human embryonic kidney cells transformed with the SV40 large T
antigen. All cells were cultured in humidified incubators at 37C and 5% CO2. A549, HEK293-FT, A375, A172 and SW620 cells were
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Gibco) with 10% FBS (Sigma), 1% penicillin/streptomycin (Lonza) and
2 mM L-glutamine (Lonza). HT-29, HPAFII and H460 cells were cultured in RPMI1640 medium (Gibco), with the same supplements
as DMEM.
METHOD DETAILS
Sequence Alignment
Protein sequences of K-RAS4A/B, H-RAS and N-RASwere taken fromUniprot (The UniProt Consortium, 2019) and aligned in Clustal
Omega (Madeira et al., 2019). The alignment was further processed in JalView (Waterhouse et al., 2009) to highlight percent
sequence identity.
RNA Extraction, cDNA Synthesis and qRT-PCR
For RNA extraction, 2x105 cells were seeded in a 6-well dish and harvested the next day with the RNeasy Micro Kit (Qiagen, #74004)
according to the manufacturer’s protocol. 1 mg of RNA was reverse transcribed with the iScript cDNA synthesis Kit (BIORAD,
#1708891) according to the manufacturer’s protocol. For qRT-PCR 1 ml of diluted cDNA (1:20 or 1:80) was mixed with forward
and reverse primers (Custom primers from Invitrogen, 300 nM final concentration each) and SsoFast EvaGreen Supermix (BIORAD,
#1725204) in a 384-well plate (Axygen, #321-22-051) and run on a BIORAD CFX384.e3 Cell Chemical Biology 27, 1–13.e1–e6, August 20, 2020
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K-RAS4A fw: GAGGGAGATCCGACAATACAG;
K-RAS4A rev: TCTCGAACTAATGTATAGAAGGCATC;
K-RAS4Bfw: TTGCCTTCTAGAACAGTAGACAC;
K-RAS4B rev: CATCGTCAACACCCTGTCTTG;
Total K-RAS fw: GGAGTACAGTGCAATGAGGG;
Total K-RAS rev: CCATAGGTACATCTTCAGAGTCC;
H-RAS fw: GAACAAGTGTGACCTGGCT;
H-RAS rev: ACCAACGTGTAGAAGGCATC;
N-RAS fw: AATACATGAGGACAGGCGAAG;
N-RAS rev: GTTTCCCACTAGCACCATAGG;
GAPDH fw: CTTTGTCAAGCTCATTTCCTGG;
GAPDH rev: TCTTCCTCTTGTGCTCTTGC.
Following the PCR, melting curves were generated with default settings between 65C and 95C in 0.5C steps at 5 sec intervals.
Melting curvesweremanually analysed for purity of thePCRproduct, i.e. consistencyof ampliconmelting temperature betweendifferent
samples and peak distribution. Fold changes of transcripts were calculated by the 2-DDCt method (Livak and Schmittgen, 2001).
Cell Line Transfection and Transduction
For retrovirusproduction, 3.2mgpCMV-gag-pol (Cell Biolabs,RV-111), 2.2mgpCMV-VSV-G (Cell Biolabs,RV-110) and6mgof respec-
tive pBabeD plasmids (Flag-aHRAS, DU57190; Flag-VHL-aHRAS, DU57191; Flag-VHL, DU54477; aGFP16, DU54238; Flag-VHL-
aGFP16, DU54295) were co-transfected in roughly 70% confluent HEK293-FT cells cultured on a 10-cm dish. Plasmids were mixed
with 600 ml Opti-MEM (Gibco) and 24 ml of 1 mg/ml polyethyleneimine (Polysciences) dissolved in 25 mMHEPES pH 7.5. The mixture
was vigorously vortexed for 15 s and incubated for 20 min at room temperature. The volume was adjusted to 10 ml with DMEM and
added to FT cells. After 24 h, mediumwas exchanged to DMEMor RPMI, depending on the target cell growth medium. After an addi-
tional 24 h, themediumwasharvested andfiltered througha0.45mmMinisart syringe filter (Sartorius). The supernatantwas added to a
plate of roughly 70% confluent target cells in a 1:10–1:4 dilution (in respective medium) in the presence of 8 mg/ml polybrene (Sigma).
After 24 h, growth medium was exchanged with fresh medium containing 2 mg/ml puromycin, to select transduced cells. Puromycin
was removed from the medium after 48 h. For inhibitor experiments cells were treated with cycloheximide (100mg/ml; SigmaAldrich,
C1988), MLN4924 (1mM, 24 hours, MRC-PPU Reagents and Services), MG132 (40mM, 14 hours, abcam, ab141003), Bortezomib
(10mM, 14 hours, LC Laboratories, B-1408) or DMSO (adjusted to match respective inhibitor; SigmaAldrich, D2650).
Cells were lysed on ice, by washing once with PBS and scraping in lysis buffer (50 mM Tris–HCl pH 7.5, 0.27 M sucrose, 150 mM
NaCl, 1 mM EGTA, 1 mM EDTA, 1 mM sodium orthovanadate, 1 mM sodium b-glycerophosphate, 50 mM sodium fluoride, 5 mM
sodium pyrophosphate, 1% (v/v) Triton X-100 and 0.5% Nonidet P-40) supplemented with protease inhibitors (Roche; 1 tablet/
25 ml of lysis buffer). Protein content from cleared cell lysates was determined with Pierce Detergent Compatible Bradford Assay
Kit (Thermo Fisher). Lysates were processed further or frozen and stored at -20C.
CRISPR/Cas9
For generation of N-terminal GFP knock-in A549 cell lines the KRAS locus was targeted with a dual guide approach (Fulcher et al.,
2019) (using the sense guide (pBabeD vector, DU54976): GCGAATATGATCCAACAATAG; antisense guide (pX335 vector, DU54980):
GCTGAATTAGCTGTATCGTCA; and the GFP-KRAS donor (pMK-RQ vector, DU57406). Briefly, 1 mg of each of the guideRNA plas-
mids and 3 mg of the donor plasmid were co-transfected into A549 cells. Plasmids were mixed with 1 ml of Opti-MEM (Gibco) and
20 ml of 1mg/ml polyethyleneimine (Polysciences), vortexed vigorously for 15 s and added to 70%confluent cells in a 10-cmdish. The
next day, cells were selected in puromycin (2.5 mg/ml) for 48 h and re-transfected with the same plasmids once they reached 70%
confluence. Single GFP positive cells were obtained by FACS sorting and surviving single cell cloneswere screened by genomic DNA
based PCR and Western blot to validate homozygous knock-in of the GFP-tag on the endogenous KRAS gene. For PCR based
screening the following primers were used: Fw: ATCCAAGAGAACTACTGCCATGATGC;
Rv:CATGACCTTCAAGGTGTCTTACAGGTC.PCRproductsofpositivecloneswereclonedwith theStrataClonePCRCloningKit (Agi-
lent) into the supplied vector system, according to the manufacturer’s protocol. Sequencing of positive clones was carried out by the
MRC-PPU DNA Sequencing and Services with a custom primer close to the RAS mutation site (Rv: CAAAGAATGGTCCTGCACCAG).
SDS PAGE and Western Blotting
Cell lysates were adjusted to uniform protein concentration and mixed with 6x reducing Laemmli SDS sample buffer (Fisher
Scientific). 10-20 mg of total lysate protein, or immunoprecipitates were resolved by SDS polyacrylamide gel electrophoeresis
(PAGE). After PAGE, proteins were transferred onto methanol activated PVDF membrane (Immobilon-P or Immobilon-FL, Merck)
in Tris/glycine buffer containing 20% methanol in a tank blotting system for 85 min at a constant voltage of 85 V. The membranes
were then re-incubated with methanol for 2 minutes and stained with Ponceau S solution to gauge uniform protein transfer (Sigma).
After de-stainingmembranes in TBS-T (50mMTris–HCl pH 7.5, 150mMNaCl, 0.1%Tween-20), they were blocked for 1 h in 5%non-Cell Chemical Biology 27, 1–13.e1–e6, August 20, 2020 e4
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TBS-T, membranes were incubated with respective HRP-conjugated (CST) or fluorescently labelled (Biorad) secondary antibodies
for 1 h, washed again 3x10 min in TBS-T and developed on a ChemiDoc gel imaging system (Biorad) using the respective channels.
HRP-conjugated blots were incubated with Immobilon Western Chemiluminescent HRP Substrate (Millipore).
Immunoprecipitation
Cell lysates were adjusted to 1 mg/ml in lysis buffer. Either GFP-trap beads (ChromoTek) or Anti-FLAG-M2-Affinity agarose resin (Sig-
maAldrich) was equilibrated with lysis buffer. 300-500 mg of total protein was added to 10-15 ml of beads (50% slurry) and incubated
for an hour at 4Cunder agitation. Centrifugation steps at 200xgwere done at 4C for 2minutes. Supernatant (flowthrough) was sepa-
rated from beads, and beads were washed 3-5 times in lysis buffer. Proteins were eluted in lysis buffer containing Laemmli SDS sam-
ple buffer by boiling at 95C for 5 minutes.
Antibodies
Antibodies were purchased from Thermo Fisher (Alpha tubulin, MA1-80189; rat-HRP, 31470; B-RAF, 702187), Abcam (panRAS,
ab206969; HIF1a, ab1), Sigma (K-RAS4B, WH0003845M1; Flag-HRP, A8592-.2MG; GFP, 11814460001), CST (GAPDH, 2118S;
ERK1/2, 9102S; phospho ERK1/2 (T202/Y204), 9106S; MEK1/2, 4694S; phospho MEK1/2 (S221), 2338S; AKT, 9272S ; phosphor AKT
(S473), 12694S; phosphoEGF receptor (Y1068), 3777; c-myc, 5605; rabbit-HRP, 7074S;mouse-HRP, 7076S), SantaCruz (EGF receptor,
sc-03-G) and Bio-Rad (rabbit starbright 700, 12004161). Primary antibodies were generally used in 1:1,000 dilutions in 5%milk TBS-T,
apart from RAS (1:500), and GAPDH & alpha-tubulin (1:5,000). Secondary antibodies were used in a 1:5,000 dilution in 5%milk TBS-T.
Other primary antibodies recognizing different RAS species were obtained from Proteintech (N-RAS, 10724-1-AP; H-RAS, 18295-1-
AP; K-RAS2B, 16155-1-AP;K-RAS2A, 16156-1-AP) and Invitrogen (H-RAS, PA5-22392;K-RAS, 415700). Antibodies for immunofluores-
cence were purchased from MBL/Caltag Medsystems (GFP, 598), Abcam (ATPB, ab14730), BD Biosciences (P120 Catenin, 610133),
Sigma (Flag-M2, F1804) and Thermo Fisher (AlexaFluor488 [donkey anti-rabbit], A21206; AlexaFluor594 [goat anti-mouse], A11005).
Immunofluorescence
Cells were seeded in a 12-well dish onto cover slips and grown over night. The next day, cells were washed twice in PBS and fixed for
10minutes in 4% formaldehyde/PBS (Sigma). Coverslipswerewashed inDMEM (Gibco) containing 10mMHEPES followedby a 10min
incubation.Coverslipswerewashed inPBSandpermeabilised for 3min ineither0.2%NP-40/PBSor0.2%TritonX-100/PBS.Coverslips
were washed twice in PBS and blocked for 15 min in 3%BSA (Sigma) in PBS. Primary antibody incubation was done for 1-2 h at room
temperature at appropriate antibodydilutions in blocking solution. Residual antibodywaswashed away in 0.2%Tween/PBS (3x10min).
Secondary antibody incubationwas done for 30min at 1:300 antibody dilution in the dark. The samewash steps were repeated, but the
firstwashcontainedDAPI (0.5–1mg in 10ml, SigmaAldrich). Finally, coverslipsweredipped inwater, air driedandmountedonslideswith
Vectashield (Vector Laboratories). FluorescencesignalswereanalysedonaDeltavisionWidefieldmicroscope (GE). Imagesweredecon-
volved using the default settings of softWoRx Imaging software and further analysed using OMERO (Allan et al., 2012).
Cell Proliferation Assays
After trypsinization, live cell numbers were determined in a Neubauer haemocytometer in the presence of trypan blue. Cell numbers
were adjusted to 5000 cells per ml in the respective growth medium. 5000 cells were added per well of a 12-well dish, and each line
was grown in triplicates. After 7 days, relative cell numbers were determined by crystal violet staining. In short, cells were washed in
PBS, fixed for 5 min in fixing buffer (10% methanol, 10% acetic acid), washed in PBS again and incubated for 30-60 min in crystal
violet solution (0.5% crystal violet in 20% methanol). Plates were dipped in tap water to remove stain and air dried overnight. Plates
were scanned on a Licor Odyssey using the 700 nm channel. Subsequently, 1 ml methanol was added to each well and plates were
incubated shaking for 30min. Depending on the colour of 1 set of cells, 100-200 ml of supernatant was loaded in triplicate on a 96-well
plate and absorbance at 570 nm was measured in an Epoch microplate spectrophotometer (BioTek). Values were normalized to the
untreated sample and a one-way ANOVA analysis with Dunnett’s multiple comparisons test was done.
Flow Cytometric Analysis
Cells were trypsinized, washed and resuspended in PBS containing 1% FBS. Cells were then analysed on a FACS Canto II flow cy-
tometer. Cells were analysed with the following gating strategy: (i) cells: in a plot of FSC-A vs. SSC-A, a gate was drawn surrounding
the major population of cells, removing debris and dead cells. (ii) single cells: in a plot of FSC-A vs. FSC-W, a gate was drawn around
an area corresponding to single cells. (iii) in the ‘single cells’ population on a GFP-A vs. PE-A plot a gate was drawn around GFP-
positive cells in A549GFPKRAS sample, using WT A549 cells as a negative control. Gates (i) and (ii) were adjusted to the individual
cell lines. Gate (iii) was kept unchanged within an experiment.
Sample preparation for Tandem Mass Tag (TMT) Labelling
Transduced and selected A549 cells were processed for TMT labelling as described previously (Tovell et al., 2019). In short, samples
were lysed in 8MUrea and 50mMAmmonium bicarbonate containing buffer, cleared after benzonase treatment, reduced with 5mM
DTT at 45C for 30 min, alkylated with 10 mM iodoacetamide at room temperature in the dark for 20 min), quenched by addition of
5mMDTT, digested with Lys-C (1:200 (w/w), Lys-C/protein) for 4 h at 30C, diluted with 50mMAmmonium bicarbonate to 1.5M finale5 Cell Chemical Biology 27, 1–13.e1–e6, August 20, 2020
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stop the digestion. The acidified digest samples were desalted on 200 mg Sep-PAK tC18 cartridges, and the eluents were dried by
using speed vacuum centrifugation (Thermo). Tandem Mass Tag labelling was performed according to the manufacturer’s protocol
using the TMT Labelling Kit (Thermo, 90110). The complete labelled samples were then mixed and fractionated with high pH reverse
phase C18 chromatography using an Ultimate 3000 high-pressure liquid chromatography system (Dionex) at a flow rate of 569 ml/min
using two buffers: A (10 mM ammonium formate, pH 10) and B (80% ACN, 10 mM ammonium formate, pH 10). Briefly, the desalted
TMT labelled peptides were resuspended in 200 mL of buffer A (10 mM ammonium formate, pH10) and fractionated on a C18 reverse
phase column (4.6 3 250 mm, 3.5 mm, Waters) with a gradient as follows: 3% B to 12.5 % B in 10 min, 12.5% to 40% buffer B in
45 min, 40% B to 60% B in 25 min, 60% B to 80% B in 10 min, 80% B to 100% B in 2.5 min, 100% for 5 min, ramping to 3% B
in 2.5 min and then 3% for 10 min. A total of 90 fractions were collected and then concatenated into 30 fractions, which were further
desalted over C18 StageTips and speed vacuum dried prior to LC-MS/MS analysis.
LC-MS/MS Mass Spectrometry
LC-MS/MSanalysis was done as described previously (Tovell et al., 2019), with a ThermoDionexUltimate 3000RSLCNano liquid chro-
matography instrument. Peptides were quantitated by Nanodrop and the sample was dissolved in 0.1% formic acid. 1 mg of each frac-
tion was loaded on C18 trap column with 3% ACN/0.1% TFA at 5 ul/min flow rate. Peptides were separated over an EASY-Spray col-
umn (C18, 2mm, 75mm x 50cm) with an integrated nano electrospray emitter (flow rate 300nl/min). Peptide separation was done over
180min with a segmented gradient: the first 10 fractions starting from 5%30%buffer B in 125min (Note: themiddle 10 fractions start-
ing from 7% and the last 10 fractions starting from 10%), 30%45% buffer B in 30 min, 45%95% buffer B for 5 min, followed by a
5min 95%B. Elutedpeptideswere analysedon anOrbitrap Fusion Lumos (ThermoFisher Scientific, San Jose, CA)mass spectrometer.
Spray voltage was set to 2 kV, RF lens level was set at 30%, and ion transfer tube temperature was set to 275 C. The Orbitrap Fusion
Lumos was operated in positive ion data-dependent mode with synchronous precursor selection (SPS)-MS3 analysis for reporter ion
quantitation. The mass spectrometer was operated in data-dependent Top speed mode with 3 seconds per cycle. The full scan was
performed in the range of 350–1500 m/z at nominal resolution of 120 000 at 200 m/z and AGC set to 4x105 with maximal injection
time 50 ms, followed by selection of the most intense ions above an intensity threshold of 5000 for collision-induced dissociation
(CID)-MS2 fragmentation in the linear ion trapwith 35%normalized collision energy. The isolationwidthwas set to 0.7 m/zwith nooffset.
Dynamic 6 exclusion was set to 60 seconds. Monoisotopic precursor selection was set to peptide, maximum injection time was set to
50msec. Charge states between 2 to 7were included forMS2 fragmentation. The top 5 fragment ions fromeachMS2 scanwas notched
out for MS3. TheMS3 scanwere performedwith an isolation width of 2 m/z in the quadrupole, normalised HCD collision energy of 65%
and analysis of fragment ions in the orbitrap using 50 000 resolving power with auto normal range scan from m/z 100 to 500 and AGC
target of 5x104. The maximal injection time for MS3 scan was set to 86 ms.
LC-MS/MS Data Analysis
LC-MS/MS data analysis was done as described previously (Tovell et al., 2019). All acquired LC-MS data were analysed using Pro-
teome Discoverer software v.2.2 (Thermo Fisher Scientific) with Mascot search engine. Maximum missed cleavages for trypsin
digestion was set to 2. Precursor mass tolerance was set to 20 ppm. Fragment ion tolerance was set to 0.6 Da. Carbamidomethy-
lation on cysteine (+57.021 Da) and TMT-10plex tags on N termini as well as lysine (+229.163 Da) were set as static modifications.
Variable modifications were set as oxidation on methionine (+15.995 Da). Data were searched against a complete UniProt Human
Proteome (Reviewed 20,143 entry downloaded at Nov 2018). Peptide spectral match (PSM) error rates with a 1% FDR were deter-
mined by target-decoy strategy coupled to Percolator modelling of true and false matches. Both unique and razor peptides were
used for quantitation. Reporter ion abundances were corrected for isotopic impurities based on the manufacturer’s data sheets. Re-
porter ionswere quantified fromMS3 scans using an integration tolerance of 20 ppmwith themost confident centroid setting. Signal-
to-noise (S/N) valueswere used to represent the reporter ion abundancewith a co-isolation threshold of 50%and an average reporter
S/N threshold of 10 and above required for quantitation from each MS3 spectra to be used. The S/N value of each reporter ions from
each PSMwere used to represent the abundance of the localised phosphorylation sites. The precursor spectra with higher than 25%
co-isolation were further manually checked. The total peptide amount was used for the normalisation. Protein ratios were calculated
from medians of summed sample abundances of replicate groups. Standard deviations were calculated from three biological repli-
cate values. The standard deviation of three biological replicates lower than 25% were used for further analyses. To determine the
significant differences between different treatments, ANOVA model was used for statistical significance analysis.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was done usingGraphPad Prism. For comparison of two groups, unpaired, two-tailed t-tests were performed. For
comparison of more than two groups an Ordinary ANOVA with post-hoc Dunnett’s multiple comparisons test was performed. A p-
value < 0.05 was considered statistically significant. Sample sizes are indicated in the respective figure legend.Cell Chemical Biology 27, 1–13.e1–e6, August 20, 2020 e6
